| Literature DB >> 34884268 |
Emilio Bouza1, Arístides de Alarcón2, María Carmen Fariñas3, Juan Gálvez4, Miguel Ángel Goenaga5, Francisco Gutiérrez-Díez6, Javier Hortal7, José Lasso8, Carlos A Mestres9, José M Miró10, Enrique Navas11, Mercedes Nieto12, Antonio Parra13, Enrique Pérez de la Sota14, Hugo Rodríguez-Abella15, Marta Rodríguez-Créixems1, Jorge Rodríguez-Roda16, Gemma Sánchez Espín17, Dolores Sousa18, Carlos Velasco García de Sierra19, Patricia Muñoz1, Martha Kestler1.
Abstract
This is a consensus document of the Spanish Society of Cardiovascular Infections (SEICAV), the Spanish Society of Thoracic and Cardiovascular Surgery (SECTCV) and the Biomedical Research Centre Network for Respiratory Diseases (CIBERES). These three entities have brought together a multidisciplinary group of experts that includes anaesthesiologists, cardiac and cardiothoracic surgeons, clinical microbiologists, infectious diseases and intensive care specialists, internal medicine doctors and radiologists. Despite the clinical and economic consequences of sternal wound infections, to date, there are no specific guidelines for the prevention, diagnosis and management of mediastinitis based on a multidisciplinary consensus. The purpose of the present document is to provide evidence-based guidance on the most effective diagnosis and management of patients who have experienced or are at risk of developing a post-surgical mediastinitis infection in order to optimise patient outcomes and the process of care. The intended users of the document are health care providers who help patients make decisions regarding their treatment, aiming to optimise the benefits and minimise any harm as well as the workload.Entities:
Keywords: cardiac surgery; infection; mediastinitis; post-surgical mediastinitis; sternal wound infections; surgical wound infection
Year: 2021 PMID: 34884268 PMCID: PMC8658224 DOI: 10.3390/jcm10235566
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Levels of evidence derived from the articles reviewed.
| Quality of Evidence | |
|---|---|
| 1++ | High quality meta-analysis, SR of a RCT or a RCT with a very low risk of bias |
| 1+ | Well-conducted meta-analysis, SR of a RCT or a RCT with a low risk of bias |
| 1− | Meta-analyses, SR, RCT or RCT with a high risk of bias |
| 2++ | High-quality SR of case–control or cohort studies |
| 2+ | High quality or cohort case and control studies with very low risk of confusion or bias and a high probability that the relationship is causal |
| 2− | Well-executed case–control or cohort studies with low risk of confusion or bias and a moderate probability that the relationship is causal |
| 3 | Non-analytical studies (e.g., clinical cases, case series) |
| 4 | Expert opinion(s) |
Studies with a “−” level of evidence should not be used as a basis for a recommendation. Adapted from the Scottish Intercollegiate Guidelines Network. RCT = randomised control trial; SR = systematic review.
Classification of recommendations.
| Degree of Recommendation | Risk vs. Profit | Methodological Strength of Evidence |
|---|---|---|
| Strong recommendation, high quality of evidence | Benefits clearly outweigh the risk | Consistent evidence from randomised controlled trials without major limitations or exceptionally strong evidence from observational studies |
| Strong recommendation, moderate quality evidence | Benefits clearly outweigh the risk | Evidence from randomised controlled trials with relevant limitations (inconsistent results, methodological weaknesses, indirect or imprecise) or very strong evidence from observational studies |
| Strong recommendation, low or very low quality of evidence | Benefits clearly outweigh the risk | Evidence of at least one critical outcome from observational studies, case series or randomised controlled trials, with serious defects or indirect evidence |
| Weak recommendation, high quality of evidence | Close benefit/risk balance | Consistent evidence from randomised controlled trials without major limitations or exceptionally strong evidence from observational studies |
| Weak recommendation, moderate quality of evidence | Close benefit/risk balance | Evidence from randomised controlled trials with relevant limitations (inconsistent results, methodological weaknesses, indirect or imprecise) or very strong evidence from observational studies |
| Weak recommendation, low or very low quality of evidence | Uncertain risk/benefit estimates; possible close benefit/risk balance | Evidence of at least one critical outcome from observational studies, case series or randomised controlled trials, with serious defects or indirect evidence |
Recommendations for empirical antibiotic treatment.
| Recommendation | Dose |
|---|---|
| * Daptomycin or vancomycin + piperacillin-tazobactam or meropenem (depending on the centre) | High doses (8–10 mg/kg/day) of i.v. daptomycin |
| Allergy: |
* Treatments should be reviewed considering to the results of the microbiological cultures and clinical progression.
Recommendations * for the treatment of mediastinitis as per the aetiological agent. Treatment must always be carried out with the advice of an expert in infectious diseases and adjusted to the sensitivity of each microorganism in each centre.
| Microorganism | First Choice | Alternatives |
|---|---|---|
| Gram-positive cocci | ||
| Methicillin-sensitive | Cloxacillin/cefazolin | |
| Methicillin-resistant | Vancomycin or daptomycin + cloxacillin/ceftaroline | Ceftaroline |
|
| Not high aminoglycoside resistance | Vancomycin + gentamicin |
| High aminoglycoside resistance | Daptomycin + Fosfomycin | |
|
| Daptomycin + ampicillin | Daptomycin + tigecycline |
| Gram-negative bacilli including multidrug resistant microorganisms | ||
|
| According to antibiogram | Tigecycline + amikacin or imipenem |
|
| According to antibiogram | Ceftazidime + amikacin |
|
| Tigecycline +/− colistin or meropenem if susceptible | |
| Carbapenemase-producing | Expert consensus is required Ceftazidime-avibactam if susceptible. | Expert consensus |
| Fungi | ||
|
| Fluconazole/Voriconazole | Echinocandins |
|
| Voriconazole | Liposomal amphotericin |
* Before prescribing, always search for drug interactions and patient allergies. ** Oral antimicrobials (after 2–3 weeks of IV treatment and according to antibiogram): Linezolid/tedizolid, trimethoprim-sulfamethoxazole, clindamycin, quinolones, fusidic acid with/without rifampicin.